Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clearside Biomedical Inc CLSD

Healthcare
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or... see more

Recent & Breaking News (NDAQ:CLSD)

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

GlobeNewswire 10 days ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2024

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

GlobeNewswire March 18, 2024

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 12, 2024

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

GlobeNewswire February 29, 2024

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

GlobeNewswire February 7, 2024

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

GlobeNewswire December 14, 2023

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

GlobeNewswire November 8, 2023

Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

GlobeNewswire November 7, 2023

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

GlobeNewswire November 3, 2023

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

GlobeNewswire November 2, 2023

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

GlobeNewswire November 1, 2023

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

GlobeNewswire October 31, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

GlobeNewswire October 16, 2023

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

GlobeNewswire October 4, 2023

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

GlobeNewswire October 3, 2023

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

GlobeNewswire September 19, 2023

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2023

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

GlobeNewswire August 2, 2023